| Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-14 15:00:58 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 |
BOULDER, Colo. , May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET. |
prnewswire.com |
2025-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights |
– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – – On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 – – Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 – BOULDER, Colo. , May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business highlights. |
prnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Why Edgewise Therapeutics Stock Popped This Week |
On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compiled by S&P Global Market Intelligence, its share price vaulted nearly 14% higher across the week. |
fool.com |
2025-05-02 23:07:08 |
Czytaj oryginał (ang.) |
| These 5 Insiders Are Buying During Market Chaos |
Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S. |
247wallst.com |
2025-04-08 12:45:58 |
Czytaj oryginał (ang.) |
| EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data |
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500. |
zacks.com |
2025-04-07 17:20:31 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On |
The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook for Edgewise Therapeutics, Inc. remains positive with multiple catalysts rapidly approaching for EWTX stock. Key milestones include 12-week data from the CIRRUS-HCM study in 2H 2025 and a phase 3 study initiation in 1H 2026. |
seekingalpha.com |
2025-04-02 20:54:24 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study |
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM). |
benzinga.com |
2025-04-02 16:27:12 |
Czytaj oryginał (ang.) |
| Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged |
Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor's Business Daily. |
investors.com |
2025-04-02 13:16:42 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock |
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. |
prnewswire.com |
2025-04-02 10:22:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) |
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM. |
prnewswire.com |
2025-04-02 10:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time |
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET. |
prnewswire.com |
2025-03-26 18:45:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Anatole, Dallas, TX from March. |
businesswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics: More Expensive Now, But Much More Derisked |
Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data. Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials. |
seekingalpha.com |
2025-03-10 15:36:32 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that u. |
businesswire.com |
2025-03-04 10:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights. “Closing out 2024 with positive Phase 2 CANYON results, completing enrollment in GRAND CANYON and advancing CIRRUS-HCM, we are well positioned in 2025 across our muscular dystrophy and cardiovascular portfolio,” said Kevin Koch, Ph.D., President and Chief Exe. |
businesswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data |
Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities. |
seekingalpha.com |
2024-12-31 16:09:40 |
Czytaj oryginał (ang.) |
| EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study |
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage. |
zacks.com |
2024-12-17 12:20:34 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease |
On Monday, Edgewise Therapeutics, Inc., EWTX revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic disorder that causes progressive muscle weakness. |
benzinga.com |
2024-12-16 13:56:24 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. The trial met its primary endpoint of change from baseline in CK. C. |
businesswire.com |
2024-12-16 08:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company's relationship with Dr. Han Phan at Rare Disease Research. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dr. Phan based on a 2024 site inspection related to her work with another company. This warning letter is unrelated to any Edgewise clinical trial or data. None of the. |
businesswire.com |
2024-12-05 16:32:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that. |
businesswire.com |
2024-11-26 08:00:00 |
Czytaj oryginał (ang.) |
| Analysts Think There's Still Time To Get In On Edgewise |
Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. |
benzinga.com |
2024-09-30 16:12:48 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge |
Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. |
benzinga.com |
2024-09-25 15:50:05 |
Czytaj oryginał (ang.) |
| Analyst Think There's Still Time to Get in on Edgewise, Up 332% |
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. |
marketbeat.com |
2024-09-25 13:00:20 |
Czytaj oryginał (ang.) |
| Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? |
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors. |
benzinga.com |
2024-09-22 21:34:03 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge |
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. |
marketbeat.com |
2024-09-19 18:16:15 |
Czytaj oryginał (ang.) |
| EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies |
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients. |
zacks.com |
2024-09-19 17:01:25 |
Czytaj oryginał (ang.) |
| Why Edgewise Therapeutics Stock Is Up 50% on Thursday |
Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This market is currently underserved, largely because many heart drugs can cause other cardiac problems. |
fool.com |
2024-09-19 16:55:46 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment |
On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstructive hypertrophic cardiomyopathy. |
benzinga.com |
2024-09-19 14:19:10 |
Czytaj oryginał (ang.) |
| Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip |
Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. |
investors.com |
2024-09-19 13:22:12 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM. In the pla. |
businesswire.com |
2024-09-19 11:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D.,. |
businesswire.com |
2024-09-17 20:01:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal |
Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation. |
seekingalpha.com |
2024-08-05 18:38:23 |
Czytaj oryginał (ang.) |
| 7 Small-Cap Stocks to Buy for Large-Scale Gains |
Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential. |
investorplace.com |
2024-07-30 16:25:52 |
Czytaj oryginał (ang.) |
| Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy |
Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-07-17 17:00:37 |
Czytaj oryginał (ang.) |